Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study
about
Pharmacogenetics as a tool to tailor antiretroviral therapy: A reviewIndividualization of antiretroviral therapy--pharmacogenomic aspectInsights into CYP2B6-mediated drug-drug interactionsComparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypesEffect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV InfectionSingle Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive IndividualsPharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypesFrench 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Factors associated with remaining on initial randomized efavirenz-containing regimens.ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohortInfluence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.Pharmacogenomics of antimicrobial agents.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successLow-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersPlasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to AnalysisGenome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapyPharmacogenetics of drug-metabolizing enzymes in US Hispanics.Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisInvestigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.Global HIV/AIDS Clinical and Translational PharmacologyA single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Individualization of antiretroviral therapy.Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
P2860
Q26797938-CADE1E77-734C-42DA-850C-28B385DC2C1CQ28070574-9244E9B6-E9C4-443E-8434-83C9DA43D3B5Q28078857-E874D4FD-1A3B-469F-A656-7F84D89DD10DQ28539169-04715429-9397-426A-9073-B5B9684FE5D4Q28548638-7C741DA2-700C-4D3C-ACD9-D99263B9B7F2Q28554250-A055D580-6647-490F-849A-4B291400E6AAQ31150044-82396BFE-90BA-4354-9ED3-19C989D1C767Q33775397-29552520-C72F-4862-BEB3-532C7D0E3BD0Q33909980-F7DE3F62-21FD-486D-A190-8FFB9C43B49AQ33909996-E503BE45-4714-4EEF-835F-A7EC8A985869Q34057466-6B7E3133-D97B-4AEB-9AAF-BE2F9D2CF9E7Q34307589-BFC967C0-8CEA-4A8F-9126-E4E38E659AF5Q34378368-486C6B32-A178-4FA0-9B1F-318865E0183FQ34571645-73F362A5-B387-42B0-8B1E-2D32B06C3004Q34756398-B545E1AF-8C97-42EF-8B9D-84427FAD72B6Q34870233-2F21D609-F703-4D1B-9F0D-BB26C8C64A80Q34977413-78446A9D-E337-47F8-88A8-B2AD6F6CFCF6Q35043700-C8C5E48C-4EE2-47FA-95A5-AF4B8E09307FQ35056873-FB9942F7-E162-49DC-8D08-1401F90877B6Q35065867-103C92E8-2E89-4128-8F90-F5CDDBD6D40DQ35114865-BAF2A4F5-CFCE-4397-8C50-6FC2C2EC3A14Q35185164-6F947402-67C9-4F63-B596-8CF30FCBAD98Q35288691-156DE225-F497-4D32-A350-66867BF694C2Q35364120-A8C8F662-888A-4E9B-9EB8-1ABA74F2114CQ35518558-160B97D8-D7D6-4801-B5C1-37066457FE1AQ35547723-7051AE90-488B-47E7-96A1-4D922EF10CE2Q35654120-A8CF6905-F5BA-44B6-80E4-431A17FAD4A9Q35661209-DCCF2EDE-112B-4DE5-83D3-6AAFDE14F400Q35791633-80F8DD91-7889-488A-82F6-36C41DA44D30Q35846143-067DE126-2297-4160-A088-7FA69FDF545EQ35878413-143085C1-821F-411A-9FE4-181E8BA80B45Q35887051-5F3F5B5C-AC22-4368-AD56-FBF0AAFACB12Q35947529-B2E02153-1DFE-4382-BE5D-2B796F9260B8Q36079108-16698229-F109-4390-B1C4-A1EFEE0F25E6Q36125023-BBAFED7D-1BD0-40A3-8D24-B70B5662D637Q36305444-B7001563-A2E7-4B78-A6F7-33BD40875C60Q36441423-4114E4DB-0BF4-493D-8CC0-BB06750F7462Q36558501-B28641D0-28DA-420E-BFDC-991EA8A8824BQ36650954-663A39B4-1127-49A3-B44D-E951E6CDA99BQ36657589-636DC421-69DF-40D0-8D76-9702F4E91C23
P2860
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@ast
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@en
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@nl
type
label
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@ast
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@en
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@nl
prefLabel
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@ast
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@en
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@nl
P2093
P2860
P50
P921
P3181
P356
P1476
Effect of CYP2B6, ABCB1, and C ...... DS Clinical Trials Group study
@en
P2093
Alison A Motsinger-Reif
David Clifford
David W Haas
Edward P Acosta
Gene D Morse
Gregory K Robbins
Heather J Ribaudo
Matthias Schwab
Michel Eichelbaum
P2860
P304
P3181
P356
10.1086/655470
P407
P577
2010-09-01T00:00:00Z